We are live on ! Find out more
GCVRZ

Sanofi Contingent Value Rights
GCVRZ

Delisted

GCVRZ was delisted on the 3rd of March, 2020.

Back to rankings

115 hedge funds and large institutions have $57M invested in Sanofi Contingent Value Rights in 2017 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 20 increasing their positions, 12 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 12

57% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 7

4% more funds holding

Funds holding: 111 → 115 (+4)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

15% less capital invested

Capital invested by funds: $67.2M → $57M (-$10.1M)

Holders
115
Holders Change
+4
Holders Change %
+3.6%
% of All Funds
2.87%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
11
Increased
20
Reduced
12
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCM
Stonehill Capital Management
New York
+$2.55M
2
HCM
Highbridge Capital Management
New York
+$229K
3
SAM
Silverback Asset Management
North Carolina
+$184K
4
PAAMCP
Pacific Alternative Asset Management Company (PAAMCO)
California
+$112K
5
AFM
Anson Funds Management
Texas
+$108K

Top Sellers

Rank Fund Capital Flow
1
PC
PointState Capital
New York
-$3.29M
2
RL
Ruffer LLP
United Kingdom
-$6K
3
FHA
Flagship Harbor Advisors
Massachusetts
-$5.31K
4
UBS Group
UBS Group
Switzerland
-$1.01K
5
BWM
Baystate Wealth Management
Massachusetts
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
TA
26
Teton Advisors
New York
$152K – – –
PAAMCP
27
Pacific Alternative Asset Management Company (PAAMCO)
California
$147K +$112K +275,500 +247%
Susquehanna International Group
28
Susquehanna International Group
Pennsylvania
$91K +$45.5K +111,518 +87%
Wells Fargo
29
Wells Fargo
California
$61K +$638 +1,563 +1%
YCM
30
Yakira Capital Management
Connecticut
$59K – – –
First Eagle Investment Management
31
First Eagle Investment Management
New York
$56K – – –
BCM
32
Basso Capital Management
Connecticut
$48K – – –
Bank of America
33
Bank of America
North Carolina
$45K -$571 -1,400 -1%
UBS Group
34
UBS Group
Switzerland
$41K -$1.01K -2,468 -2%
GI
35
GAMCO Investors
Connecticut
$24K -$816 -2,000 -3%
JP Morgan Chase
36
JP Morgan Chase
New York
$23K – – –
Citadel Advisors
37
Citadel Advisors
Florida
$20K +$2.83K +6,941 +15%
Korea Investment Corp
38
Korea Investment Corp
South Korea
$19K – – –
OCM
39
Osterweis Capital Management
California
$19K – – –
ZIG
40
Zuckerman Investment Group
Illinois
$16K -$316 -774 -2%
Commonwealth Equity Services
41
Commonwealth Equity Services
Massachusetts
$16K +$45 +111 +0.3%
DBG
42
De Burlo Group
Massachusetts
$15K – – –
Ameriprise
43
Ameriprise
Minnesota
$14K -$174 -426 -1%
CHAM
44
Clear Harbor Asset Management
Connecticut
$13K – – –
Morgan Stanley
45
Morgan Stanley
New York
$12K +$1.86K +4,550 +15%
SDWMA
46
Schneider Downs Wealth Management Advisors
Pennsylvania
$10K – – –
VKH
47
Virtu KCG Holdings
New York
$9K +$9.34K +22,891 New
FHA
48
Flagship Harbor Advisors
Massachusetts
$6K -$5.31K -13,000 -47%
ISL
49
Ingalls & Snyder LLC
New York
$6K -$127 -310 -2%
CS
50
Credit Suisse
Switzerland
$6K – – –
1
2
3 4

GCVRZ Hedge Fund Activity: Q2 2017 in Review

115 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q2 2017, worth a combined $57M — down 15% from $67.2M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new GCVRZ positions and 7 closed out — a net gain of 4 holders — while 20 added to existing stakes and 12 trimmed.

The largest buyer was Stonehill Capital Management, adding an estimated $2.55M. The largest seller was PointState Capital, exiting entirely with an estimated $3.29M sold.

  • 115 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q2 2017, up from 111 in Q1 2017.
  • Funds reported $57M of Sanofi Contingent Value Rights stock for Q2 2017, down 15% quarter-over-quarter.
  • 11 funds opened new Sanofi Contingent Value Rights positions in Q2 2017 and 7 closed out, a net change of +4 holders.
  • The largest Sanofi Contingent Value Rights buyer in Q2 2017 was Stonehill Capital Management, an estimated $2.55M added.
  • The largest Sanofi Contingent Value Rights seller in Q2 2017 was PointState Capital, an estimated $3.29M sold.

Based on aggregated 13F filings for Q2 2017.